Objective-Cerebral vasoreactivity (CVR) is a key factor in maintenance of continuous cerebral perfusion and a marker of (micro)vascular damage. We aimed to determine the longitudinal relation between CVR and the risk of dementia in the general population. Approach and Results-We determined CVR in nondemented participants who underwent transcranial Doppler with induced hypercapnia from 1997 to 1999, as part of the ongoing population-based Rotterdam Study. We used a Cox model to determine the risk of dementia in relation to CVR, adjusted for age, sex, cardiovascular risk factors, and carotid intima-media thickness. We furthermore determined decline on a cognitive test battery in relation to CVR, using linear mixed models. Among 1629 participants (mean±SD age 70.6±6.2 years, 46.2% female) with a mean follow-up of 11.5 years, 209 were diagnosed with dementia, of whom 171 had Alzheimer disease. Higher CVR at baseline was associated with lower risk of dementia (adjusted hazard ratio, 95% confidence interval, per SD increase: 0.87, 0.75-1.00) and Alzheimer disease (adjusted hazard ratio, 0.84; 0.71-0.99). This association was more profound in APOEε4 carriers than in noncarriers (adjusted hazard ratio for all dementia: 0.77, 0.60-0.98 versus 0.89, 0.73-1.07). Performance on cognitive tests at baseline was better with higher CVR (g-factor: P=0.02), but during 3 cognitive assessments over 11 years of follow-up, higher CVR at baseline was associated with less decline in test scores on the Stroop reading and interference tasks in APOEε4 carriers only (P=0.01 and 0.02, respectively).
A bout 44 million people worldwide are living with dementia, and because of a rapidly aging population this number is predicted to nearly double every 20 years until 2050. 1, 2 Consequently, the social and economic burden of dementia will increase enormously, unless preventive or curative measures can be established. Cardiovascular health is increasingly acknowledged as a key determinant in prevention of dementia, including Alzheimer disease (AD). 3, 4 Yet, the mechanism by which vascular damage leads to cognitive decline remains largely unknown.
Although many studies have related cognitive function to static markers of cerebrovascular pathology, such as small vessel disease on magnetic resonance imaging and the retinal vasculature, few provide a functional measure of cerebral vascular disease. Cerebral vasoreactivity (CVR) reflects the ability of the cerebral arterioles and capillaries to dilate in response to increased neuronal metabolic demand, 5 and can be quantified in vivo using transcranial Doppler (TCD) or magnetic resonance imaging. Vasoreactivity is essential for maintenance of continuous cerebral perfusion, and impaired vasoreactivity is associated with (cardiovascular) mortality in the general population 6 and risk of stroke in the presence of flow-limiting carotid artery stenosis. 7 In addition, lower vasoreactivity correlates with higher volumes of cerebral white matter lesions, 8 which are strongly associated with cognitive decline and dementia. 9 Several small cross-sectional studies have found CVR to be reduced in patients with dementia or mild cognitive impairment compared with healthy controls, [10] [11] [12] but its impact on cognitive decline and the risk of dementia is uncertain.
We hypothesized that impaired CVR precedes dementia, and aimed to determine the association of CVR with cognitive decline and the risk of dementia in a population-based study.
Materials and Methods
This study is embedded within the Rotterdam study, an ongoing population-based cohort study in The Netherlands. TCD investigation with induction of hypercapnia was added to the core protocol for the second follow-up examination, from July 1997 to December 1999. Materials and Methods are available in the online-only Data Supplement.
Results
Among 2569 eligible participants undergoing TCD with induced hypercapnia, no temporal bone window was present on either side in 632 (24.6%) individuals. Measurements could not be completed in 214 (8.3%) cases because of participants feeling anxious or unwell (n=54), lack of time (n=3), or other undocumented causes (n=157). In addition, in 94 participants we failed to obtain a reliable measurement of CVR despite adequate CO 2 induction, thus leaving a total of 1629 cases for analysis. Baseline characteristics of participants in comparison with nonparticipants are shown in Table 1 .
CVR was strongly impaired in current smokers and to a lesser extent in participants with a history of hypertension or diabetes mellitus. Conversely, higher systolic and diastolic blood pressure at the time of examination, higher levels of high-density lipoprotein, and higher body mass index were significantly associated with higher CVR at baseline (for a full table, please see the online-only Data Supplement). These associations were similar for APOEε4 carriers and noncarriers (data not shown).
During a mean follow-up time of 11.5 (SD 4.3) years, 209 individuals developed dementia, of whom 158 (75.6%) were diagnosed having AD, 15 (7.2%) vascular dementia, 13 (6.2%) mixed Alzheimer and vascular pathology, 6 (2.9%) another type of dementia, and 17 (8.1%) remained undetermined. Of all incident dementia cases, 30 were preceded by a stroke, a median 4.5 years before diagnosis of dementia.
Higher CVR at baseline was associated with a lower risk of dementia during follow-up, as illustrated in Figure 1 by Kaplan-Meier estimates and fully adjusted hazard ratios per quartile of CVR. This was similar for all dementia and AD only ( Figure 1 ; Table 2 ). The association was more profound in APOEε4 carriers compared with noncarriers (adjusted hazard ratio, 95% confidence interval, per SD increase: 0.77, 0.60-0.98 versus 0.89, 0.73-1.07; Table 2 ), although formal statistical tests for interaction were not significant (for all dementia and AD: P>0.25). Effect estimates were broadly similar for those above and below the median age, and remained essentially unchanged after censoring for stroke, excluding participants with onset of dementia within 4 years of follow-up, or excluding those with exhausted CVR ( Table 2) .
Of all participants, 1608 (98.7%) underwent cognitive testing at baseline. Higher CVR was associated with better performance on cognitive tests at baseline (g-factor: P=0.02), with larger effect estimates for APOEε4 carriers than noncarriers ( Figure 2 -for a full table please see the online-only Data Supplement). Repeated cognitive testing was carried out in 1094 of 1251 (87.5%) and 699 of 910 (76.8%) of surviving, nondemented, stroke-free individuals after a mean follow-up of 4.5 (SD, 0.5) years and 11.0 (SD, 0.3) years, respectively. Overall, CVR was not associated with decline on any of the cognitive tests. However, in APOEε4 carriers higher baseline CVR was indicative of less decline in test scores on Stroop reading and Stroop interference tasks, whereas no such associations were seen in noncarriers ( Figure 2 -for a full table please see the online-only Data Supplement).
Discussion
In this large population-based study of initially nondemented participants, higher CVR was associated with a lower longterm risk of developing dementia and AD. Those with higher vasoreactivity performed better on cognitive tests at baseline also, whereas for decline on cognitive tests during follow-up this association was found in APOEε4 carriers only.
Our study shows that vasoreactivity is impaired at an early, subclinical stage of dementia, thereby linking the cerebral microcirculation to the pathophysiology of dementia. Although many studies have assessed the cross-sectional association between vasoreactivity and cognition, we are not aware of any studies determining the risk of cognitive decline in relation to vasoreactivity longitudinally. Vasoreactivity depends on endothelial cell, pericyte, and vascular smooth muscle cell function to maintain cerebral perfusion. Potential explanatory mechanisms for the association between vasoreactivity and dementia, therefore, include a direct functional consequence of impaired vasoreactivity, or an indirect result of endothelial cell and blood-brain barrier dysfunction via other pathways, or a combination of both. Our observation that vasoreactivity remained associated with dementia after excluding dementia cases within the first 4 years of follow-up, supports at least in part direct causality.
In case of impaired flow regulation with reduced vasoreactivity, both (episodic) hypoperfusion and uncontrolled hyperaemia can lead to a reduction in tissue oxygenation and hypoxia. 13 Hypoxia triggers expression of various inflammatory cytokines via activation of hypoxia-inducible transcription factors. 14 Inflammatory cytokines subsequently activate microglia, 15 inducing release of proinflammatory neurotoxic factors (eg, interleukin [IL]-1β and tumor necrosis factor α) and oxidative stress. This may explain why in patients with AD, the cerebral microvasculature releases higher levels of various inflammatory factors, including tumor necrosis factor α, transforming growth factor β, various ILs, and matrix-metalloproteinases. 16 In addition, brain endothelial cells exposed to amyloid-β40 upregulate expression of monocyte chemotactic protein 1, IL-1β, and IL-6 genes in vitro, and upregulation of these genes is seen in vivo in patients with AD and cerebral amyloid angiopathy. 17 As amyloid-β also promotes migration of inflammatory cells across the blood-brain barrier, 18, 19 detrimental effects of inflammation in the central nervous system may be enhanced in the presence of amyloid-β.
Furthermore, hypoxia-inducible transcription factor renders endothelial cells responsive to proangiogenic factors, including vascular endothelial growth factor, angiopoietins and platelet-derived growth factor. These factors are vital for maintaining blood-brain barrier integrity through regulating endothelial cell and pericyte function in angiogenesis. 20 Permeability of the endothelial cell layer increases in response to vascular endothelial growth factor, and pericytes detach from the vessel wall and basement membrane in response to angiopoietin-2, mediated by matrix-metalloproteinases. 21 In addition, coverage of newly shaped vessels by pericytes is dependent on signaling by platelet-derived growth factor B, angiopoietin-1, transforming growth factor β, and Notch. 21 Because pericyte deficiency is associated with age-related vascular damage that precedes neurodegeneration, 22 loosening of junctions between endothelial cells because of aberrant proangiogenic signaling may be detrimental for vascular and neuronal cell function. Hypoxia is furthermore found to lead to aberrant angiogenesis and microvascular degeneration in patients with AD, by suppressing expression of the mesenchyme homeobox 2 gene in brain endothelial cells. 23 The same study found that mesenchyme homeobox 2-deficient mice showed vascular degeneration and poor amyloid-β clearance. 23 Taken together with the inhibition of capillary angiogenesis by amyloid, 24, 25 this may link faulty capillary angiogenesis to hallmarks of AD pathology. As most extracellular clearance of amyloid-β goes via the blood-brain barrier, 26 blood-brain barrier disruption could allow more rapid accumulation of amyloid. Indeed, in a large memory clinical cohort, deposition of amyloid was found aggravated in patients with cerebral small vessel disease. 27 Finally, endothelial dysfunction has previously been suggested as a direct link between vasoreactivity and dementia, possibly because of impaired release or function of endothelial vasodilators or vasoconstrictors. 28 As a major vasodilator, endothelial nitric oxide is vital in control of local blood flow, and seems particularly relevant in the brain to minimize neuronal damage in case of focal ischemia. 29 Interestingly, nitric oxide has also been shown to modulate expression of amyloid precursor protein and β-site amyloid precursor protein-cleaving enzyme 1 in mice. 29 Endothelial nitric oxide synthase levels correlate well with τ and amyloid burden in patients with AD, 30 further suggesting a role of endothelial dysfunction in dementia.
Our results suggest that the association between cerebral microvascular function and cognition is more profound in carriers of the APOEε4 allele, the major genetic risk factor for AD. 31 This is in line with a recent cross-sectional study, that found the impact of APOEε4 on cognition to be amplified in the presence of impaired vasoreactivity. 32 As imaging markers of both microvascular disease and cognitive function, such as white matter lesions and microbleeds, 9, 33 are abundant in APOEε4 carriers, 34 specific APOE-related mechanisms may account for these observations. In fact, mechanisms described above in relation to inflammation, pericyte function, and blood-brain barrier integrity have been reported of particular relevance in APOEε4 carriers. Studies in mice have implicated APOEε4-mediated blood-brain barrier disruption in neurodegeneration, via a proinflammatory cyclophilin A-nuclear factor-κB-matrix-metalloproteinase 9 pathway in pericytes. 35 In humans, cognitively healthy APOEε4 carriers showed higher age-dependent blood-brain barrier breakdown than APOEε3 carriers, 36 and whereas in patients with AD both APOEε4 and APOEε3 carriers had more pericyte degeneration than in healthy controls, the difference was most profound in the former. 37 In addition, in a large memory clinic cohort, amyloid deposition in those with small vessel disease was most aggravated in APOEε4 carriers. 30 Associations between vasoreactivity and dementia remained similar overall, and became stronger for APOEε4 carriers after adjustment for traditional cardiovascular risk factors. Conversely, the associations of cardiovascular risk factors with the risk of dementia were broadly unchanged by adjustment for vasoreactivity. This suggests that in addition to vascular risk factors, other mechanisms underlie impaired vasoreactivity, which is supported by the notion that vascular risk factors explain only 2% of variance in white matter lesion burden, 38 and 4.2% of variance in vasoreactivity in our study. Nevertheless, our study confirms lower vasoreactivity in those with a history of hypertension, probably because of pulsatile pressure changes associated with chronic hypertension. 13, 39 On a cellular level, this could be related to pericyte degeneration, endothelial swelling, and thickening of basement membranes, as found in animal models of hypertension. 40 Because chronic hypertension can shift the upper and lower limits of cerebral autoregulation toward higher blood pressure levels, 41 this might explain why we found higher vasoreactivity with increasing blood pressure on examination. Although the adaptive mechanism of vasoreactivity may, in part, protect the brain against hypertension, it may also render its vulnerable to cerebral hypoperfusion, 42 and vasoreactivity may thus be an important modifier of the effect of antihypertensive treatment on prevention of cognitive decline. We furthermore found lower vasoreactivity to be associated with diabetes mellitus and current smoking. Nicotine use increases expression of adhesion molecules in the capillary endothelium and leukocyte rolling. 40 For diabetes mellitus, preclinical studies suggest loss of pericytes and thickening of basement membranes, as well as hyperviscosity, reduced erythrocyte deformability and glycocalix degradation by oxidative stress and hyperglycaemia, which may all contribute to microvascular damage and reduced vasoreactivity. 40 Finally, lipid metabolism is vital in vascular homeostasis, potentially contributing to many of the mechanisms described above, and may be of particular relevance in relation to APOE genotype. Exposure to cardiovascular risk factors is long acknowledged to decrease activity of endothelial nitric oxide, which may affect dementia pathology, as discussed above.
Several drugs have been proposed to have potential benefit on blood-brain barrier integrity and endothelial cell function. 43 Of these, observational studies have shown a reduced risk of dementia associated with long-term use of nonsteroidal anti-inflammatory drugs, statins, H2-receptor antagonists, and calcium channel blockers, which may, in part, be attributable to anti-inflammatory or antiangiogenic effects. Although none have proven effective in treatment of AD, [44] [45] [46] the effect of longterm use on prevention of dementia has not been assessed in trials. Few drugs have been tested directly for improvement of CVR, but 2 small randomized controlled trials in patients with recent lacunar infarcts did not show any benefit of 3-month use of high-dose atorvastatin and allopurinol on vasoreactivity. 47, 48 Another small trial assessing the effect of 1-year lisinopril versus candesartan versus hydrochlorothiazide found no significant between-group differences in vasoreactivity or vasomotor range. 49 Future observational and experimental studies should investigate potential beneficial drug classes, based on aforementioned mechanism in relation to cognition and markers of cerebrovascular permeability, in addition to lacunar stroke. Also, nonmedicinal interventions such as physical activity, diet, and other lifestyle factors may contribute to maintaining vasoreactivity. As vasoreactivity might already start to decline in adolescence in carriers of the APOEε4 allele, 50 this highlights a large potential window of opportunity for presymptomatic treatment, as well as the need for timely intervention.
Although we think our results are valid, there are certain limitations to our study to take into account. First, only a sample of the full Rotterdam Study cohort was investigated by TCD, and we cannot therefore exclude selection bias. Nonparticipants were older, more often female, and had less often smoked in the past. Because female sex and increasing age are associated with lower CVR and higher rate of dementia, 51 this might have caused underestimation of the effect. Second, participants in this study cohort did not undergo cognitive testing of the memory domain, probably most indicative of Alzheimer pathology. Third, a formal test for interaction between vasoreactivity and APOEε4 was not significant, possibly because of sample size. Fourth, we assessed medial cerebral artery flow velocity, whereas posterior cerebral artery flow may be more indicative of changes in the hippocampus and amygdala. Moreover, TCD does not allow region-specific assessment of CVR, which is probably more sensitive in detecting changes in relation to cognitive decline. 11 Consequently, our findings may underestimate the impact of impaired vasoreactivity in regions of the brain that are particularly affected in AD.
In conclusion, CVR is associated with an increased risk of dementia in the general population. This suggests that cerebral microvascular function is impaired at an early, subclinical stage of dementia, and that preservation of microvascular integrity may deter cognitive decline.
